Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Fiche publication
Date publication
mai 2024
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L
Lien Pubmed
Résumé
The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with CD.
Mots clés
Crohn’s disease, effectiveness, maintenance therapy, risankizumab
Référence
Clin Gastroenterol Hepatol. 2024 05 8;: